Literature DB >> 2449458

Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis.

R Hohlfeld1, K V Toyka, L L Miner, S L Walgrave, B M Conti-Tronconi.   

Abstract

Autoimmune helper T lymphocytes were selected from the blood of two myasthenic patients of different HLA-DR type, using acetylcholine receptor (AChR) from Torpedo californica. These polyclonal T cell lines were tested for reactivity with three synthetic peptides corresponding to the NH2-terminal region of the human AChR alpha subunit. This segment is a good candidate for T cell epitopes since it has a propensity to form an amphipathic alpha helix. The peptides elicited 10-30% of the response induced by native Torpedo AChR. Different peptides were recognized by the autoreactive T cells of the two patients. These results suggest that the NH2-terminal region of the AChR alpha chain contains T cell-stimulating epitopes, and that the T cell autoimmune response in myasthenia gravis, like the B cell response, is heterogeneous.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449458      PMCID: PMC442511          DOI: 10.1172/JCI113369

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  T-cell antigenic sites tend to be amphipathic structures.

Authors:  C DeLisi; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 2.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

Authors:  R H Schwartz
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

Review 3.  The structure of T-cell epitopes.

Authors:  A M Livingstone; C G Fathman
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

Review 4.  Protein antigenic structures recognized by T cells: potential applications to vaccine design.

Authors:  J A Berzofsky; K B Cease; J L Cornette; J L Spouge; H Margalit; I J Berkower; M F Good; L H Miller; C DeLisi
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

5.  Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells.

Authors:  A Sette; S Buus; S Colon; J A Smith; C Miles; H M Grey
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

Review 6.  The nicotinic cholinergic receptor: correlation of molecular structure with functional properties.

Authors:  B M Conti-Tronconi; M A Raftery
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

7.  The main immunogenic region of acetylcholine receptors does not provoke the formation of antibodies of a predominant idiotype.

Authors:  J A Killen; S M Hochschwender; J M Lindstrom
Journal:  J Neuroimmunol       Date:  1985-08       Impact factor: 3.478

8.  Autoimmune human T lymphocytes specific for acetylcholine receptor.

Authors:  R Hohlfeld; K V Toyka; K Heininger; H Grosse-Wilde; I Kalies
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

9.  Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Authors:  U A Besinger; K V Toyka; M Hömberg; K Heininger; R Hohlfeld; A Fateh-Moghadam
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

10.  Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines.

Authors:  R Hohlfeld; I Kalies; B Kohleisen; K Heininger; B Conti-Tronconi; K V Toyka
Journal:  Neurology       Date:  1986-05       Impact factor: 9.910

View more
  9 in total

1.  Phenotypic and functional characterization of T cells from patients with myasthenia gravis.

Authors:  F Mokhtarian; M Pino; W Ofosu-Appiah; D Grob
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Proteins with epitopes of the acetylcholine receptor in epithelial cell cultures of thymomas in myasthenia gravis.

Authors:  A Marx; T Kirchner; F Hoppe; R O'Connor; B Schalke; S Tzartos; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

4.  Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.

Authors:  A Melms; S Chrestel; B C Schalke; H Wekerle; A Mauron; M Ballivet; T Barkas
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

5.  In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.

Authors:  S Brocke; C Brautbar; L Steinman; O Abramsky; J Rothbard; D Neumann; S Fuchs; E Mozes
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 6.  Structural basis of antigen recognition by T lymphocytes. Implications for vaccines.

Authors:  J A Berzofsky
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

7.  Schwann cells and myasthenia gravis. Preferential uptake of soluble and membrane-bound AChR by normal and immortalized Schwann cells, and immunogenic presentation to AChR-specific T line lymphocytes.

Authors:  Y P Zhang; S Porter; H Wekerle
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

8.  Generation of recombinant, enzymatically active human thyroid peroxidase and its recognition by antibodies in the sera of patients with Hashimoto's thyroiditis.

Authors:  K D Kaufman; B Rapoport; P Seto; G D Chazenbalk; R P Magnusson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis.

Authors:  B Carlsson; J Wallin; R Pirskanen; G Matell; C I Smith
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.